Amgen Inc (AMGN) Financials
Key financial figures for Amgen Inc (Q2 2026).
Amgen posted Q2 2026 revenue of $10.05 billion (up 10% year over year) and non-GAAP EPS of $6.29, beating consensus and prompting a raise to full-year 2026 guidance. Total revenue reached $10.05B, up 10% year over year, with GAAP EPS of $4.37 (up 65%) and non-GAAP EPS of $6.29, ahead of the $5.62 consensus estimate. Amgen raised full-year 2026 guidance to $38.2B-$39.4B in total revenue (from $37.1B-$38.5B) and $22.30-$23.50 non-GAAP EPS (from $21.70-$23.10). Growth products (Repatha, Evenity, Tezspire, Tepezza) all grew double digits year over year, offsetting continued erosion in mature brands like Enbrel. Free cash flow was $3.5 billion for the quarter, generated from $4.0B of operating cash flow less $0.5B of capital expenditures. On the outlook: Raised FY2026 guidance: total revenue $38.2B-$39.4B (from $37.1B-$38.5B), non-GAAP EPS $22.30-$23.50 (from $21.70-$23.10), GAAP EPS $15.80-$17.08, capital expenditures approximately $2.6B, share repurchases not to exceed $3.0B. Figures are for Q2 2026, as Amgen Inc. reported them.
- Revenue
- $10.1B
- Net Income
- $2.4B
- EPS
- $4.40
- Total Assets
- $95.6B
- Operating Cash Flow
- $4.0B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $10.1B | $2.4B | $4.37 | 34.95% | $3.5B |
| Q1 FY2026 | $8.6B | $1.8B | $3.34 | 30.94% | $1.5B |
| Q4 FY2025 | $9.9B | $1.3B | $2.45 | 39.83% | $961M |
| Q3 FY2025 | $9.6B | $3.2B | $5.93 | 26.43% | $4.2B |
| Q2 FY2025 | $9.2B | $1.4B | $2.65 | 28.84% | $1.9B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $36.7B | $7.7B | $14.23 | 29.06% | $8.1B |
| FY2024 | $33.4B | $4.1B | $7.56 | 21.71% | $10.4B |
| FY2023 | $28.2B | $6.7B | $12.49 | 28.01% | $7.4B |
Frequently asked questions
What was Amgen Inc.'s revenue last quarter?
Amgen Inc. reported revenue of $10.05 billion for Q2 FY2026, up 9.7% from the same period a year earlier.
Is Amgen Inc. profitable?
Yes. Amgen Inc. reported net income of $2.38 billion for Q2 FY2026, a net margin of 23.62% on revenue.
How has Amgen Inc.'s margin trended?
Operating margin was 34.95% in Q2 FY2026, compared with 28.84% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Amgen Inc. generate?
Amgen Inc. generated free cash flow of $3.49 billion in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Amgen Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.